AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10793015
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 2 weeks
Trial: 8640423
Drug: Individual Child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Child and Parent Cognitive‐Behavioral Treatment (CBT)
Trial: 29532784
Drug: Family Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Therapy (FT)
Trial: 9286780
Drug: Prostacyclin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin infusion
Trial: 28077047
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion (EI) of cefepime 2g IV every 8h with 3h infusion
Trial: 22221937
Drug: 10% to
RxNorm normalized name: SULFUR 10% TOP BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% to 20% preemptive warfarin dose reduction
Trial: 21161329
Drug: Reactive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive warfarin dose adjustment
Trial: 20187454
Drug: CT‐guided percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐guided percutaneous fibrin glue therapy of arachnoid cysts (group B, 30 cases)
Trial: 17512795
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen administration for more than 3 months
Trial: 17512795
Drug: Short-term oxygen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oxygen administration for 2 weeks
Trial: 16138333
Drug: Short-course high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course high-dose methylprednisolone (HDMP) at a daily dose of 30 mg/kg starting 4 days before consolidation therapy
Trial: 16138333
Drug: Short-course high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course high-dose methylprednisolone (HDMP)
Trial: 7791814
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cyclosporine and methotrexate
Trial: 27004301
Drug: Vitamin D₂
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D₂ (20,000 IU weekly)
Trial: 24195210
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment combined with semiconductor laser irradiation
Trial: 12594313
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin, alternating with ifosfamide and etoposide
Trial: 12594313
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin
Trial: 9102242
Drug: Multiple puncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple puncture and intraarticular antibiotic therapy
Trial: 9102242
Drug: Arthrotomy from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrotomy from antero-lateral approach, suction drainage for 24-48 hours, systemic intravenous antibiotic therapy, abduction position of extremity in Frejka pillow and early physiotherapy
Trial: 1992877
Drug: Elevated ESR
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated ESR (greater than 30 mm/h) after therapy
Trial: 6337624
Drug: Grating stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grating stimulation (CAM therapy)
Trial: 29769167
Drug: Post-PCI bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-PCI bivalirudin infusion
Trial: 19095215
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by axillary lymph node dissection (ALND)
Trial: 12139535
Drug: Intrathecal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal clonidine 150 mg
Trial: 12139535
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 150 mg
Trial: 18070786
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine 15 mg
Trial: 2522919
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion SR 2508 (etanidazole)
Trial: 332100
Drug: Intravenous fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fructose treatment
Trial: 31937347
Drug: Placebo (48-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (48-hour intravenous infusion starting at 6 to 18 hours after injury)
Trial: 19300388
Drug: Soy group
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy group (2 g of soybeans per kilogram body weight for 7 days)
Trial: 15557666
Drug: Three-component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-component acellular pertussis vaccine
Trial: 164510
Drug: 1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 percent papaverine cream
Trial: 23084254
Drug: Supervised multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised multimodal exercise intervention (9 hours weekly for 6 weeks)
Trial: 18849016
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level less than 12 g/dL
Trial: 18849016
Drug: Neutrophil count
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrophil count 4 x 10(9)/L or greater
Trial: 22240283
Drug: Conatumumab-doxorubicin (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conatumumab-doxorubicin (doxorubicin 75 mg/m2 + conatumumab 15 mg/kg every 3 weeks)
Trial: 11239634
Drug: Unheated patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unheated patch plus ibuprofen
Trial: 17369807
Drug: Nucleotide supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide supplement (E)
Trial: 9796354
Drug: Ceruletide infusion
RxNorm normalized name: ceruletide diethylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceruletide infusion cholescintigraphy
Trial: 7705012
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg tid
Trial: 7705012
Drug: Ceftazidime 1000
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1000 mg tid for RTIs and 500 mg tid for UTIs
Trial: 2533786
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine + multiple doses of HBIG (Group I)
Trial: 2533786
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine + single dose of HBIG (Group II)
Trial: 2533786
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine only (Group III)
Trial: 2533786
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine only
Trial: 405902
Drug: Pilocarpine in
RxNorm normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine in 0.5% hydroxypropyl-methylcellulose solution
Trial: 405902
Drug: Pilocarpine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (both formulations)
Trial: 28697789
Drug: Intramuscular or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular or intra-arterial injection of 40 ml BM-MNC concentrate
Trial: 21989078
Drug: Metformin 1
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1 g, twice daily
Trial: 14586213
Drug: Bryostatin-1 25
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin-1 25 mug/m(2) as a 1-h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Trial: 10814771
Drug: Haloperidol 25
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 25 mg/day
Trial: 10587284
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg/day + Lorazepam 4 mg/day
Trial: 10587284
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg/day + Placebo
Trial: 1659980
Drug: Granisetron (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40 micrograms/kg intravenously before chemotherapy, with up to two further doses daily of 40 micrograms/kg if necessary)
Trial: 10919583
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily
Trial: 20816833
Drug: formoterol/beclomethasone 12/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol/beclomethasone 12/200 μg Modulite
Trial: 20816833
Drug: formoterol/budesonide 9/320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol/budesonide 9/320 μg Turbuhaler
Trial: 12838857
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial chemotherapy and radiotherapy (A group)
Trial: 27504014
Drug: 6-month, culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month, culturally tailored, U.S. Diabetes Prevention Program-based lifestyle curriculum plus stepwise addition of metformin (500 mg, twice daily)
Trial: 2197911
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (600 mg by inhalation using a Respirgard II nebulizer)
Trial: 2197911
Drug: Intravenous pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pentamidine
Trial: 265082
Drug: Topical painting
RxNorm normalized name: Castellani Paint Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical painting with potassium fluoride solution containing Al-, Fe-, and Mn-ions
Trial: 265082
Drug: Topical painting
RxNorm normalized name: Castellani Paint Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical painting with 0.2% NaF-solution
Trial: 7044620
Drug: Oestrogen/gestagen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen/gestagen alone or in combination with 1,25(OH)2D3
Trial: 25223266
Drug: MF59-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted trivalent subunit vaccine (aTIV)
Trial: 25223266
Drug: TIV-2 (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV-2 (split virion vaccine)
Trial: 25223266
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three vaccines (aTIV, TIV-1, TIV-2)
Trial: 6373441
Drug: Nimesulide 100
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg
Trial: 22421470
Drug: Tramadol chlorhydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol chlorhydrate 100 mg
Trial: 19079943
Drug: HCA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCA (2 g)
Trial: 19079943
Drug: ETO (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETO (320 mg)
Trial: 15179192
Drug: Intrahepatic cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrahepatic cisplatin at 125 mg/m
Trial: 31162031
Drug: Rituximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (5 x 500 mg until month 18)
Trial: 31162031
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg per day, gradually decreased between month 12 and 22)
Trial: 28454498
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg (once daily)
Trial: 22231013
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human albumin (HA) 20 gr infused over 1 hour
Trial: 22231013
Drug: Oral cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cabergoline (Cb2) 0.5 mg per day for 7 days starting on oocyte pickup day
Trial: 17456651
Drug: Cumulative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative morphine administration
Trial: 12140475
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate spray (FP), 50 microg two dose unit sprays, 4 times daily for 6 weeks
Trial: 12140475
Drug: Betamethasone sodium
RxNorm normalized name: Betamethasone Sodium Phosphate
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone sodium phosphate mouthrinse (BSP), 500 microg, 4 times daily for 6 weeks
Trial: 7876615
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (0, 1, and 12 months schedule for adults; 0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months for children)
Trial: 30901440
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (control group)
Trial: 30901440
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Vitamin D3 supplement (treatment group)
Trial: 30901440
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Vitamin D3 supplement (treatment group)
Trial: 28608438
Drug: NUTRITION (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRITION (oral nutritional supplementation enriched with leucine, vitamin D, and omega-3 fatty acids)
Trial: 26534930
Drug: Dopamine replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine replacement therapy (DRT)
Trial: 26534930
Drug: No dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dopamine replacement therapy (not on DRT)
Trial: 23026180
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg/day
Trial: 18923109
Drug: Risk behaviors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk behaviors including frequent public drunkenness, early age of illicit drug use, involvement in the drug economy, tattooing, injecting drugs, unprotected sex
Trial: 11859651
Drug: Levocetirizine 2.5
RxNorm normalized name: Levocetirizine 2.5mg/5mL Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 2.5 mg
Trial: 19860762
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg
Trial: 23441762
Drug: Levocetirizine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 10 mg
Trial: 3429102
Drug: 5-MOP Re-PUVA
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-MOP Re-PUVA with daily oral etretinate
Trial: 20194702
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg posaconazole oral suspension twice daily for 8 days with a high-fat meal
Trial: 10511057
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg midazolam intravenously
Trial: 10511057
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg midazolam orally
Trial: 2429908
Drug: inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inosine pranobex (Imunovir) with conventional treatment
Trial: 26081179
Drug: Single maximal
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single maximal inhalation with breath-hold (200 μg salbutamol)
Trial: 26081179
Drug: 5 tidal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 tidal breaths (200 μg salbutamol)
Trial: 11049140
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment
Trial: 18971135
Drug: Bupivacaine-soaked Spongostan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-soaked Spongostan plus local lignocaine infiltration 1% up to 20 mL
Trial: 18971135
Drug: Local lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local lignocaine infiltration 1% up to 20 mL
Trial: 12657237
Drug: Peritoneal dialysis
RxNorm normalized name: Peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal dialysis solution (1.5% dextrose)
Trial: 31771756
Drug: Multiple barriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple barriers to adherence (e.g., forgetfulness, health beliefs)
Trial: 21646910
Drug: Lactulose 30-60
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 30-60 ml twice per day (GpB)
Trial: 21646910
Drug: Probiotics 110
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics 110 billion CFU twice per day (GpC)
Trial: 21646910
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA) 6 g three times per day (GpD)
Trial: 21646910
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (GpA)
Trial: 16761194
Drug: ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (10 mg/day for 90 days)
Trial: 11430965
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg and vaginal misoprostol 800 microg (used 48 hours after mifepristone)
Trial: 11430965
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol inserted at 1, 2, or 3 days after mifepristone administration
Trial: 1351405
Drug: Neuroleptic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic drugs
Trial: 9468354
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with neuroleptics
Trial: 9468354
Drug: Noncompliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncompliance with medication
Trial: 9468354
Drug: Current drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current drug abuse
Trial: 3226418
Drug: Continuous hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with an anticancer drug
Trial: 25185603
Drug: Pseudoephedrine ER
RxNorm normalized name: pseudoephedrine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine ER 120 mg
Trial: 8813873
Drug: Imipramine 25
RxNorm normalized name: trimipramine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 25 mg
Trial: 24822235
Drug: Cyclobenzaprine 10
RxNorm normalized name: cyclobenzaprine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 10 mg
Trial: 22037770
Drug: Cannabis dose
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis dose
Trial: 22037770
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in cannabis dose
Trial: 10077720
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy (control group)
Trial: 11345031
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Ukrain (5 mg every second day, 10 injections altogether)
Trial: 11345031
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Ukrain (10 mg every second day, 10 injections altogether)